4Tissue

The annual accounts of 4Tissue for financial year 2025 show a net loss of 127% of the equity at the start of that year. The 2025 annual accounts show equity of €845,476 and a net result of -€727,036. Equity is growing by about 74% per year across the filed financial years. Its solvency ranks better than 43% of 780 sector peers (NACE 32, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.5% (low).